Robert Lechleider, serving as Chief Medical Officer for Immunome Inc. (NASDAQ:IMNM), has completed the sale of 55,000 shares of the company's common stock. Executed on July 2, 2026, the transactions generated a total value of $1,244,330. The shares were divested at prices fluctuating between $21.26 and $23.67. This activity coincides with a period of significant stock performance, as shares were trading at $24.38 on the date of the report, marking an 181% increase over the past year according to InvestingPro data. The platform's Fair Value analysis indicates that the stock is currently trading at levels that suggest overvaluation.
The divestment was not a single lump-sum transaction but was structured across multiple blocks to execute the sale. A primary block consisted of 22,714 shares, which were sold at prices ranging from $21.26 to $22.25. A subsequent block involved 16,214 shares, traded within a price range of $22.26 to $23.25. The final segment of the sale comprised 16,072 shares, executed at prices between $23.26 and $23.67. Lechleider conducted these transactions under the framework of a Rule 10b5-1 trading plan, which he adopted on March 26, 2026. This pre-arranged plan is designed to facilitate the buying and selling of company stock in compliance with securities regulations.
The sale follows a recent acquisition of stock by Lechleider through the exercise of employee stock options. Prior to the divestment, he acquired 55,000 shares at an exercise price of $8.73 per share, totaling $480,150. These options are scheduled to expire on October 26, 2033. The vesting schedule for these options was structured with 25% vesting on October 16, 2024, with the remaining shares vesting monthly over a three-year period. Following the completion of these sales, Lechleider's direct holdings in Immunome Inc. common stock stand at 15,805 shares. Additionally, he retains 290,000 unexercised employee stock options.
Despite the executive's stock sale, market analysts maintain a bullish outlook on the biotech company. Price targets for Immunome range from $30 to $40. The company has recently advanced its clinical pipeline with significant developments. Immunome submitted a New Drug Application to the U.S. Food and Drug Administration for varegacestat, a treatment intended for adults with desmoid tumors. This submission is supported by Phase 3 trial results that demonstrated an 84% reduction in the risk of disease progression or death compared to a placebo. These results were presented at the American Society of Clinical Oncology Annual Meeting, emphasizing the drug's potential impact on disease progression.
In parallel, Immunome has dosed the first patient in a Phase 1 trial for IM-1617, an antibody-drug conjugate targeting solid tumors. This trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the drug. On the financial analysis front, Truist Securities raised its price target for Immunome to $37, citing the promising potential of varegacestat in the desmoid tumor market. Barclays initiated coverage on Immunome with an overweight rating, setting a price target of $36, reflecting optimism about the company's pipeline and potential market impact.